PFIZER INC forecasts high-single-digit growth from 2029 after beating first-quarter revenue estimates with $14.45 billion on Tuesday morning. The drugmaker is pivoting toward obesity and cancer treatments to offset a 59% drop in COVID-19 vaccine sales. Investors are weighing near-term patent expirations against a pipeline that won't deliver major obesity results until after 2028.

Pipeline Pivot Targets 2029 Growth